Vineet Laboratories Ltd Stock Price Today (NSE: VINEETLAB)
Fundamental Score
Vineet Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Vineet Laboratories Ltd share price today is ₹29.06, up +0.00% on NSE/BSE as of 30 March 2026. Vineet Laboratories Ltd (VINEETLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹39.25 (Cr). The 52-week high for VINEETLAB share price is ₹49.99 and the 52-week low is ₹26.51. The company has a Return on Equity (ROE) of -89.47% and a debt-to-equity ratio of 3.01.
Vineet Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Vineet Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Vineet Laboratories Share Price Analysis: A Conservative Value Investor's Perspective
The Indian pharmaceutical sector, while generally considered defensive, requires careful due diligence. High barriers to entry exist due to stringent regulatory requirements and established brand power, but not all companies can successfully navigate this landscape. This analysis focuses on Vineet Laboratories share price, viewed through the lens of a conservative value investor prioritizing capital safety.
Currently trading at ₹30.02, Vineet Laboratories presents a challenging picture. The absence of a Price-to-Earnings (PE) ratio suggests the company is not currently profitable. More concerning is the Return on Capital Employed (ROCE) of -27.95%. This indicates a significant inefficiency in capital allocation and an inability to generate returns from invested capital. This negative ROCE directly impacts the company's moat, suggesting a weak competitive position and potential difficulties in generating future profits. A negative ROCE makes it difficult for the company to reinvest and grow, further hindering its long-term sustainability.
When comparing Vineet Laboratories Ltd to its peers, such as
Mankind Pharma Ltd, stark contrasts emerge. While specific management assessments are beyond the scope of this initial analysis, it's generally observed that leaders at companies like Mankind Pharma have demonstrably created significant shareholder value over time. The management's strategic choices and execution capabilities are crucial factors in determining long-term success, something that the negative ROCE at Vineet Laboratories prompts questions about.This assessment highlights areas of concern regarding Vineet Laboratories' financial health and competitive positioning. Further investigation is warranted to understand the underlying causes of the negative ROCE and the company's plans to address them. This analysis is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra, providing a detailed snapshot of the company's current standing. It is important to remember that this is an observational analysis and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vineet Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VINEETLAB across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Robust Profit Growth (121.86%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (-89.47%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-27.95%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (2.28%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Revenue Contraction (-8.12%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Elevated Debt Levels (D/E: 3.01)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (-2.75x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Low Promoter Commitment (15.89%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Vineet Laboratories Ltd Financial Statements
Comprehensive financial data for Vineet Laboratories Ltd including income statement, balance sheet and cash flow
About VINEETLAB (Vineet Laboratories Ltd)
Vineet Laboratories Ltd is a dynamic force within the pharmaceutical landscape, dedicated to the meticulous crafting of high-quality active pharmaceutical ingredients, specialty in...termediates, and a diverse portfolio of fine chemicals. From its state-of-the-art facilities, the company pioneers innovative methodologies and rigorous quality control protocols, ensuring that each product meets the stringent demands of both domestic and international markets. Their unwavering commitment to scientific excellence and process optimization positions them as a trusted partner for pharmaceutical companies seeking reliable and efficacious raw materials, driving advancements in drug development and patient care. Focusing on the intricate building blocks of modern medicine, Vineet Laboratories specializes in the production of key intermediates for a range of crucial APIs, including those utilized in antiviral therapies and treatments for chronic conditions. Through continuous research and development, they expand their product offerings, adapting to the evolving needs of the pharmaceutical industry. Vineet Laboratories also expertly formulates fine chemicals and reagents, catering to specialized scientific applications and supporting researchers across various disciplines. The company's dedication to precision and purity ensures that these critical compounds contribute significantly to scientific progress. Vineet Laboratories takes pride in its commitment to sustainable manufacturing practices. They prioritize environmental responsibility by implementing innovative technologies that minimize waste and optimize resource utilization. With a focus on customer satisfaction, they offer personalized solutions, ensuring that their clients receive the specific compounds they need, precisely when they need them. Vineet Laboratories fosters long-term relationships with its partners, contributing to the advancement of global healthcare by delivering reliable and consistent products.
Company Details
Key Leadership
Corporate Events
VINEETLAB Share Price: Frequently Asked Questions
What is the current share price of Vineet Laboratories Ltd (VINEETLAB)?
As of 30 Mar 2026, 12:08 pm IST, Vineet Laboratories Ltd share price is ₹29.06. The VINEETLAB stock has a market capitalisation of ₹39.25 (Cr) on NSE/BSE.
Is VINEETLAB share price Overvalued or Undervalued?
VINEETLAB share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Vineet Laboratories Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of VINEETLAB share price?
The 52-week high of VINEETLAB share price is ₹49.99 and the 52-week low is ₹26.51. These values are updated daily from NSE/BSE price data.
What factors affect the Vineet Laboratories Ltd share price?
Key factors influencing VINEETLAB share price include quarterly earnings growth (Sales Growth: -8.12%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Vineet Laboratories Ltd a good stock for long-term investment?
Vineet Laboratories Ltd shows a 5-year Profit Growth of N/A% and an ROE of -89.47%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 3.01 before investing in VINEETLAB shares.
How does Vineet Laboratories Ltd compare with its industry peers?
Vineet Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare VINEETLAB share price P/E of 0.00x and ROE of -89.47% against the industry averages to determine competitive standing.
What is the P/E ratio of VINEETLAB and what does it mean?
VINEETLAB share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is VINEETLAB performing according to Bull Run's analysis?
VINEETLAB has a Bull Run fundamental score of N/A/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does VINEETLAB belong to?
VINEETLAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Vineet Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for VINEETLAB?
VINEETLAB has an ROE of -89.47%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Vineet Laboratories Ltd generates profits from shareholders capital.
How is VINEETLAB debt-to-equity ratio and what does it indicate?
VINEETLAB has a debt-to-equity ratio of 3.01, which indicates high leverage that increases financial risk.
What is VINEETLAB dividend yield and is it a good dividend stock?
VINEETLAB offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Vineet Laboratories Ltd shares.
How has VINEETLAB share price grown over the past 5 years?
VINEETLAB has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in VINEETLAB and why does it matter?
Promoters hold 15.89% of VINEETLAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Vineet Laboratories Ltd.
What is VINEETLAB market capitalisation category?
VINEETLAB has a market capitalisation of ₹39 crores, placing it in the Small-cap category.
How volatile is VINEETLAB stock?
VINEETLAB has a beta of N/A. A beta > 1 suggests the Vineet Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is VINEETLAB operating profit margin trend?
VINEETLAB has a 5-year average Operating Profit Margin (OPM) of 2.28%, indicating the company's operational efficiency.
How is VINEETLAB quarterly performance?
Recent quarterly performance shows Vineet Laboratories Ltd YoY Sales Growth of -8.12% and YoY Profit Growth of 121.86%.
What is the institutional holding pattern in VINEETLAB?
VINEETLAB has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Vineet Laboratories Ltd stock.